Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC have?
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC has 1,714 citations in the OpenAlex counts ScholarIQ stores.
When was Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC published?
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC has 2020 year in the ScholarIQ index.
What is the open-access status of Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC?
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC has bronze oa status in the ScholarIQ index.
What is the DOI of Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC?
The DOI for Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC is on the source record.
What is the PMID of Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC?
The PMID for Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC is on the source record.
What is the OpenAlex record for Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC?
The OpenAlex for Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC is on the source record.